Related Experiment Video

Updated: Jun 29, 2026

Intravital Microscopy of Tumor-associated Vasculature Using Advanced Dorsal Skinfold Window Chambers on Transgenic Fluorescent Mice
08:52

Intravital Microscopy of Tumor-associated Vasculature Using Advanced Dorsal Skinfold Window Chambers on Transgenic Fluorescent Mice

Published on: January 19, 2018

[Tumor vasculature as a therapeutic target in non-small cell lung cancer]

Balázs Döme1, Melinda Magyar

  • 1Országos Korányi TBC és Pulmonológiai Intézet IV. Tüdogyógyászati Osztály 1529 Budapest Piheno u. 1. Országos Korányi TBC és Pulmonológiai Intézet Tumorbiológiai Osztály Budapest. domeb@yahoo.com

Magyar Onkologia
|October 11, 2008
PubMed

Insights

Targeted therapies like bevacizumab offer new hope for non-small cell lung cancer (NSCLC) patients. This review explores novel anti-angiogenic and vascular disrupting agents, alone or with chemotherapy, for improved NSCLC treatment outcomes.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Conventional treatments for non-small cell lung cancer (NSCLC) show limited survival benefits.
  • Targeted molecular therapies represent a promising new avenue for NSCLC treatment.
  • Bevacizumab, an anti-vascular endothelial growth factor (VEGF) antibody, is a key anti-angiogenic drug in NSCLC development.

Purpose of the Study:

  • To review recent advancements in targeted therapies for NSCLC.
  • To discuss the role of bevacizumab and other novel agents in NSCLC treatment.
  • To explore challenges and future directions for targeted therapies in NSCLC.

Main Methods:

  • Review of recent preclinical and clinical studies on targeted agents in NSCLC.
  • Analysis of data on bevacizumab, vascular disrupting agents (VDAs), and tyrosine kinase inhibitors.
  • Evaluation of combination therapies involving novel agents and chemotherapy.

Main Results:

  • Bevacizumab is a leading anti-angiogenic drug for NSCLC, though challenges remain.
  • Novel agents like VDAs and tyrosine kinase inhibitors show promising preclinical and clinical results.
  • Combination strategies of novel agents with chemotherapy are under investigation.

Conclusions:

  • Targeted therapies, including bevacizumab and newer agents, are crucial for advancing NSCLC treatment.
  • Further research is needed to optimize the use of these agents and overcome existing challenges.
  • Novel targeted agents hold significant potential for improving survival rates in NSCLC patients.

More Related Videos

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis09:33

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis

Published on: March 20, 2026

A Matrigel-Based Tube Formation Assay to Assess the Vasculogenic Activity of Tumor Cells04:00

A Matrigel-Based Tube Formation Assay to Assess the Vasculogenic Activity of Tumor Cells

Published on: September 7, 2011

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...